The news is directly related to Vaccitech and is likely to influence investor sentiment. While the Overweight rating suggests that Morgan Stanley expects the stock to outperform, the reduction in price target may create some uncertainty. However, as the reduction is relatively small, the overall impact on the stock's short-term price is expected to be neutral.